These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32627039)

  • 1. Dynamic evaluation of mesenchymal circulating tumor cells in patients with colorectal cancer: Clinical associations and prognostic value.
    Shi DD; Yang CG; Han S; Wang SY; Xiong B
    Oncol Rep; 2020 Aug; 44(2):757-767. PubMed ID: 32627039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patients.
    Wang L; Zhou S; Zhang W; Wang J; Wang M; Hu X; Liu F; Zhang Y; Jiang B; Yuan H
    Int J Colorectal Dis; 2019 Apr; 34(4):589-597. PubMed ID: 30627849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of circulating tumor cells in predicating the outcomes of patients with colorectal cancer.
    Chen K; Chen Z; Ou M; Wang J; Huang X; Wu Y; Zhong W; Yang J; Huang J; Huang M; Pan D
    Clinics (Sao Paulo); 2022; 77():100070. PubMed ID: 36087570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesenchymal and Phosphatase of Regenerating Liver-3 Status in Circulating Tumor Cells May Serve as a Crucial Prognostic Marker for Assessing Relapse or Metastasis in Postoperative Patients With Colorectal Cancer.
    Su P; Lai W; Liu L; Zeng Y; Xu H; Lan Q; Chu Z; Chu Z
    Clin Transl Gastroenterol; 2020 Dec; 11(12):e00265. PubMed ID: 33512811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and Therapeutic Significance of Circulating Tumor Cell Phenotype Detection Based on Epithelial-Mesenchymal Transition Markers in Early and Midstage Colorectal Cancer First-Line Chemotherapy.
    Lu G; Lu Z; Li C; Huang X; Luo Q
    Comput Math Methods Med; 2021; 2021():2294562. PubMed ID: 34777560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers combined with clinicopathological risk has potential to better predict recurrence in stage III breast cancer treated with neoadjuvant chemotherapy: a pilot study.
    Du KY; Wu S; Ma X; Liu Y
    Breast Cancer Res Treat; 2024 Oct; 207(3):517-527. PubMed ID: 38990453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of CD133
    Fang C; Fan C; Wang C; Huang Q; Meng W; Yu Y; Yang L; Hu J; Li Y; Mo X; Zhou Z
    Cancer Med; 2017 Dec; 6(12):2850-2857. PubMed ID: 29105339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin.
    Lee DW; Han SW; Bae JM; Jang H; Han H; Kim H; Bang D; Jeong SY; Park KJ; Kang GH; Kim TY
    Clin Cancer Res; 2019 Oct; 25(20):6141-6147. PubMed ID: 31285374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis.
    Yokobori T; Iinuma H; Shimamura T; Imoto S; Sugimachi K; Ishii H; Iwatsuki M; Ota D; Ohkuma M; Iwaya T; Nishida N; Kogo R; Sudo T; Tanaka F; Shibata K; Toh H; Sato T; Barnard GF; Fukagawa T; Yamamoto S; Nakanishi H; Sasaki S; Miyano S; Watanabe T; Kuwano H; Mimori K; Pantel K; Mori M
    Cancer Res; 2013 Apr; 73(7):2059-69. PubMed ID: 23378342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
    Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
    Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of lymphovascular invasion in stage II colorectal cancer patients with an inadequate examination of lymph nodes.
    Gao Z; Cao H; Xu X; Wang Q; Wu Y; Lu Q
    World J Surg Oncol; 2021 Apr; 19(1):125. PubMed ID: 33866973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between the cyclooxygenase-2 expression in circulating tumor cells and the clinicopathological features of patients with colorectal cancer.
    Cai J; Huang L; Huang J; Kang L; Lin H; Huang P; Zhu P; Wang J; Dong J; Wang L; Xian CJ
    J Cell Biochem; 2019 Apr; 120(4):4935-4941. PubMed ID: 30260024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
    Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
    Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Role of Circulating Tumor Cells during Induction Chemotherapy Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patients with Locally Advanced Oral and Oropharyngeal Squamous Cell Cancer.
    Inhestern J; Oertel K; Stemmann V; Schmalenberg H; Dietz A; Rotter N; Veit J; Görner M; Sudhoff H; Junghanß C; Wittekindt C; Pachmann K; Guntinas-Lichius O
    PLoS One; 2015; 10(7):e0132901. PubMed ID: 26186556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High stromal nicotinamide N-methyltransferase (NNMT) indicates poor prognosis in colorectal cancer.
    Song M; Li Y; Miao M; Zhang F; Yuan H; Cao F; Chang W; Shi H; Song C
    Cancer Med; 2020 Mar; 9(6):2030-2038. PubMed ID: 31989785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of chemotherapy and operation in patients with colorectal neuroendocrine carcinoma.
    Wu Z; Yu D; Zhao S; Gao P; Song Y; Sun Y; Chen X; Wang Z
    J Surg Res; 2018 May; 225():54-67. PubMed ID: 29605035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cells count predicts survival in colorectal cancer patients.
    Romiti A; Raffa S; Di Rocco R; Roberto M; Milano A; Zullo A; Leone L; Ranieri D; Mazzetta F; Medda E; Sarcina I; Barucca V; D'Antonio C; Durante V; Ferri M; Torrisi MR; Marchetti P
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):279-84. PubMed ID: 25267956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.